Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment

Junwei Han1, Yang Yang1, Xiangmei Li1, Jiashuo Wu1, Yuqi Sheng1, Jiayue Qiu1, Qian Wang1, Ji Li1, Yalan He1, Liang Cheng1 and Yan Zhang2

1 College of Bioinformatics Science and Technology, Harbin Medical University, China
2 School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, China

Keywords
immune and stromal scores; sex differences; sex-specific prognostic biomarkers; tumor microenvironment; tumor mutational burden

Correspondence
J. Han, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
Tel: +86 451 86615922
E-mail: hanjunwei@ems.hrbmu.edu.cn
L. Cheng, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China
Tel: +86 451 86613741
E-mail: liangcheng@hrbmu.edu.cn
Y. Zhang, School of Life Science and Technology, Computational Biology Research Center, Harbin Institute of Technology, Harbin, China
Tel: +86 451 86416944
E-mail: zhangtyo@hit.edu.cn

Junwei Han, Yang Yang and Xiangmei Li contributed equally to this work.

(Received 10 December 2021, revised 17 January 2022, accepted 25 February 2022, available online 12 March 2022)
doi:10.1002/1878-0261.13203

Abbreviations
AUC, area under the curve; BLCA, bladder urothelial carcinoma; COAD, colon adenocarcinoma; DC, dendritic cell; DLBC, diffuse large b-cell lymphoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; ICB, immune checkpoint blockade; IDC, interstitial dendritic cell; IL, interleukin; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NK, natural killer cell; PAAD, pancreatic adenocarcinoma; PD-1, programmed cell death 1; pDC, plasmacytoid dendritic cell; READ, rectum adenocarcinoma; ROC, receiver operating characteristic; SARC, sarcoma; SKCM, skin cutaneous melanoma; ssGSEA, single-sample Gene Set Enrichment Analysis; STAD, stomach adenocarcinoma; TCGA, The Cancer Genome Atlas; Tem, T effector memory cell; Tfh, follicular helper T cell; THCA, thyroid carcinoma; THYM, thymoma; TMB, tumor mutational burden; TME, tumor microenvironment; WRS, Wilcoxon rank-sum test.
1. Introduction

Sex differences in cancer initiation, progression, response to therapy, and prognosis outcome have been reported across multiple cancer types [1,2]. It has been proposed that men show higher incidence and mortality in most cancer types. For example, the mortality of urinary bladder carcinomas in men clearly increases compared with women [3]. However, there are also some cancer types that undergo a higher risk in women than in men, for example, thyroid cancer [4]. Furthermore, there are also significant differences in cancer immune responses between male and female patients in several cancer types, and women generally mount stronger innate and adaptive immune responses compared with men [5,6]. Immune checkpoint blockade (ICB) therapies targeting programmed cell death 1 (PD-1) or ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have demonstrated higher efficacy than standard therapies in several cancers [7]. Conforti et al. reported that men achieved greater efficacy from ICB therapies compared with women in randomized clinical trials including 11,351 patients with advanced or metastatic cancers [8]. This trend conforms to the situation that ICB therapies may block the immune inhibitory signals employed by tumor cells and then stimulate the body’s immune response; as women generally exhibit a stronger immune microenvironment, this may result in women receiving less therapy effect than men simply through enhancing immune response. However, Wallis et al. reported that there were no significant sex differences in terms of the efficacy of immunotherapy in 23 randomized clinical trials [9]. These conflicting results may be due to cancer patients of different sex possessing different TME and molecular features.

The TME contains many different non-cancerous cell types in addition to cancer cells, such as fibroblasts and infiltrated immune cells, which play important roles in cancer progression, metastasis, and immune therapeutic efficacy [10,11]. For example, it has been proposed that regulatory T cells (Tregs) and tumor-associated macrophages were correlated with pro-tumor functions [12,13]. B cells and natural killer (NK) cells have been shown variously positively or negatively to influence the prognosis of cancer patients [14]. Other immune cell types, such as CD8 T cells, have been proposed to be associated with improved clinical outcomes and immunotherapy efficacy [15]. Recently, several computational techniques have been developed to estimate the relative abundance of different TME cells by using gene expression profiles of bulk tumors (from microarrays or RNA sequencing). For example, single sample gene set enrichment analysis (ssGSEA) uses cell-type-specific marker gene sets to infer the cell abundance by calculating the enrichment scores [16]. ImmuCellAI is designed to estimate the abundance of immune cells by integrating the ssGSEA and least-square regression algorithms [17]. CIBERSORT quantifies cell fractions by applying the deconvolution algorithm to the signature matrices containing gene expression profiles of purified immune cells [18], and xCell integrates gene set enrichment with deconvolution approaches to enumerate the abundance of cell types [19]. These methods may help to investigate the association of TME cells with cancers and identify new immunotherapeutic biomarkers. Sex-based differences in TME might also impact immune response; however, its contribution to cancer progression and prognosis across different cancer types has not been determined comprehensively [5].

Moreover, tumor mutational burden (TMB) was proposed to be correlated with TME in hepatocellular carcinoma and tracheal adenoid cystic carcinoma [20,21]. TMB has also been shown to be correlated with response to PD-1/PD-L1 blockade in patients with diverse cancers, such as melanoma [22], nonsmall cell lung cancer [23], and urothelial carcinoma [24]. Further, Li et al. discovered large differences in mutation burden between men and women in many but not all tumor types [25]. Wang et al. reported that TMB showed significant sex differences for the immune checkpoint inhibitors response, and its predictive power was significantly better for female than for male lung cancer patients [6]. As the tumor immune features may be different in men and women for some cancers, investigation of the sex differences in these features may help to identify sex-specific immune signatures.

The availability of high-throughput molecular data (e.g., whole-exome sequencing, microarrays, RNA sequencing data) of multiple cancer types in The Cancer Genome Atlas (TCGA) data portal and the TME cell estimation methods based on bulk expression data provide an opportunity to analyze the immune features. Herein, we performed a comprehensive analysis to investigate sex-based differences of cancer immune-related features across a broad range of cancer types, including TMB, TME features (immune scores, stromal scores, tumor purity, and immune cells), somatic mutations, immune checkpoint genes, and immune functional pathways, to understand potential sex-specific immune biomarkers and their effects on cancer progression, prognosis and, immunotherapy.
2. Materials and methods

2.1. Data acquisition and processing

We obtained all TCGA cancer patients except those with sex-specific cancers (e.g., ovarian cancer, uterine cancer in women and prostate cancer, testicular cancer in men) from the GDC TCGA data portal (https://portal.gdc.cancer.gov/). The molecular data (e.g., somatic mutation, gene expression) and clinical characteristics (e.g., sex, age, tumor stage, and survival time) were downloaded accordingly. We retained the primary cancer samples for each cancer type, and samples younger than 18, older than 85 or lacking sex information were excluded from the analysis. For gene expression data, FPKM-normalized profiles were used, and all expression values were then log2 (value + 1) transformed. Genes with > 90% of samples having zero expression values were removed from the respective cancer dataset. As our analyses attempt to test the sex differences in tumor microenvironment characterization, we focused on the samples with at least moderate immune infiltration to provide a fair comparison. To do this, we applied a deconvolution-based CIBERSORT algorithm [18] to the gene expression profiles of each cancer to estimate the immune infiltration extent. The samples for each cancer dataset with an empirical CIBERSORT $P < 0.05$ were used for the following analysis. Finally, we required that each cancer type include sufficient sample sizes ($\geq 10$ for both male and female patients). Thus, we obtained 19 cancer types, including 2908 samples (1771 male and 1137 female patients) (Table S1). The above processing for sample filtering is shown in Fig. S1.

2.2. Tumor mutational burden

According to the Chalmers et al. study, TMB was defined as the number of somatic, coding, base substitution, and insertion or deletion mutations per megabase (Mb) of genome examined [26]. In our study, for each cancer type, we downloaded the somatic mutation annotation format (MAF) file (derived from Varscan2) from the GDC TCGA data portal, which is obtained from TCGA whole-exome sequencing (WES) data. Based on the MAF file, we extracted non-silent somatic mutations (nonsense, missense, splice-site mutations, stop codon read-throughs, change of start codon, frame-shift indels, inframe indels) in the protein-coding region of genes. For each sample, TMB was calculated as follows: $N_{\text{mutation}}/\text{Length}$, where $N_{\text{mutation}}$ is the number of non-silent somatic mutations and Length is the length of coding regions (Mb). In TCGA, 38 Mb is generally used as the estimate of the length of coding regions; therefore, TMB was calculated for each sample.

2.3. Inference of the infiltration levels of immune cells and the scores of stromal and immune

Recently, a number of studies have applied single-sample Gene Set Enrichment Analysis (ssGSEA) to infer the relative level of immune cell infiltration based on the cell-specific signature from RNA profiling data [27]. In the study, we downloaded 24 immune cell type-specific gene signatures from a Bindea et al. publication [28] (Table S2). Normalized gene expression data (log2-transformed FPKM) were used to infer the relative tumor infiltration levels of 24 immune cell types using the ssGSEA algorithm. For each sample, the gene signatures of each immune cell were annotated to the ranked gene list based on the gene expression, and an enrichment score in the ssGSEA algorithm was used to represent the relative infiltration level of cell. We then applied the ESTIMATE (Estimation of STromal and Immune cells in MAalignant Tumor tissues using Expression data) algorithm [29] to infer stromal and immune scores of tumor samples, which reflect the level of infiltrating stromal and immune cells. The ESTIMATE algorithm which performs the ssGSEA strategy to infer these scores based on gene expression data, and its predictive ability has been validated in large and independent datasets (e.g., TCGA). Moreover, tumor purity, which is the proportion of cancer cells in the admixture, has been found to be significantly associated with clinical features and tumor biology. The tumor purity of each tumor sample was then inferred by using the ESTIMATE algorithm by combining the stromal and immune scores.

2.4. Sex differences analysis of tumor microenvironment features

The Wilcoxon rank-sum (WRS) test was used to compare the differences in TMB, stromal score, immune score, and tumor purity between male and female patients for both pan-cancer and tumor type-specific analysis. Moreover, TMB has been proposed to be correlated with TME-related features (immune scores, stromal scores, tumor purity, and immune cells) in several cancer types [20,21]. Investigation of differential correlations of TMB with TME-related features between male and female patients may reveal new insights into the sex differences in TME. To do this, we first tested the correlation between TMB and tumor
microenvironment features (including stromal score, immune score, tumor purity, and immune cells) using Spearman correlate analysis. The differential correlation analysis was then performed by comparing the correlations of TMB with a tumor microenvironment feature (stromal score, immune score, tumor purity, or immune cells) in male patients and female patients. To test whether the correlation coefficients in males and females were significantly different, we used Fisher’s transformation method to transform correlation coefficients for each of male and female group, $r_{\text{male}}$ and $r_{\text{female}}$, into $Z_{\text{male}}$ and $Z_{\text{female}}$, respectively, using the following formula:

$$Z_{\text{male}} = \frac{1}{2} \ln \frac{1 + r_{\text{male}}}{1 - r_{\text{male}}}$$

where $r$ is the Spearman correlation coefficient between TMB and a microenvironment feature in male groups. Similarly, we transformed the coefficient $r_{\text{female}}$ into $Z_{\text{female}}$. Differences between the two correlations can be tested using the following formula:

$$Z - \text{score} = \frac{Z_{\text{male}} - Z_{\text{female}}}{\sqrt{\frac{1}{n_1 - 3} + \frac{1}{n_2 - 3}}}$$

where $n_1$ and $n_2$ are the numbers of male and female patients. The Z-value has an approximately Gaussian distribution [30] and the $P$-value can be obtained with standard normal distribution according to the Z-score.

The gene expression values and immune cell infiltration levels were compared in the male and female patients using an unpaired two-sided $t$-test for each cancer type, and the $P$-values were adjusted using the false discovery rate (FDR) method proposed by Benjamini and Hochberg [31].

### 2.5. Identification of sex differences in immune function pathways

The immune function pathways were downloaded from the ImmPort database (https://www.immport.org/shared/home). The GSEA method was applied to identify the immune function pathways of sex differences for each cancer type. Specifically, we compared the gene expression values between female and male patients with the $t$-test, and the gene sets of immune pathways were respectively assigned to a ranked gene list based on the T-score of expression values. If the genes in a pathway were enriched at the top or bottom of the list, the pathway will tend to be female-biased or male-biased. For each pathway, the normalized pathway enrichment score, its corresponding $P$-value, and FDR were calculated through a permutation test in a cancer type.

### 2.6. Identification of the immune cells driven by sex-biased mutation genes

We first identified the sex-biased mutation genes. For a cancer type, we focused on non-silent somatic mutations (nonsense, missense, splice-site mutations, stop codon read-throughs, change of start codon, frame-shift indels, and inframe indels) in the protein-coding region of genes. A binary gene mutation matrix was constructed according to the MAF file, whose element is 1 (true) if any mutation occurs in a particular gene in a particular sample; otherwise it is 0 (false). To provide potential biological significance and detecting power in our analysis, the genes with more than 5% mutation frequency were retained in each cancer type. Pearson’s Chi-square test (continuity correction was used if needed) was used to compare gene mutation versus non-mutation status between male and female patients. The $P$-values were then adjusted with the FDR method [31]; FDR < 0.25 was considered significant.

We then identified the immune cell responses triggered by sex-biased mutation genes. The multivariate logistic regression analysis was performed to estimate the effect of sex-biased mutation genes on immune cells in the individual cancer type.

### 2.7. Prognostic models of sex-specific immune cells

As the immune cells for male and female patients of cancer may be different, inference of sex-specific prognostic signature of immune cells is important. Associations between the infiltration level of each immune cell type and survival were tested using a univariate Cox proportional hazard regression model in male and female patients, respectively. With Cox $P$-value < 0.05, the male- and female-specific prognostic cells were obtained in male and female patients, respectively. A male- or female-specific risk score for every patient in male or female groups was calculated using a prognostic score model based on the infiltration levels of the immune cells. The prognostic score model was as follows:

$$\text{Riskscore} = \sum_{k \in S} \beta_k a_k$$

where $S$ is a set of male- or female-specific prognostic cells; $a_k$ is the infiltration level of cell $k$; $\beta_k$ is the
regression coefficient of the univariate Cox proportional hazard regression model estimated on $a_k$ and the overall survival data in male or female patient groups. A high-risk score indicates poor survival for patients. According to the median of male- or female-specific risk scores, male and female patients were classified into high-risk and low-risk groups. Kaplan–Meier curves for male- or female-specific survival were generated in male and female patient groups, and were compared using the log-rank test.

3. Results

We focused on primary cancer samples with at least moderate immune infiltration. The CIBERSORT algorithm was used to estimate the immune infiltration extent of cancer (see Materials and methods). With CIBERSORT $P < 0.05$, we obtained 19 cancer types from TCGA with sufficient male and female sample sizes ($\geq 10$ for both); the cancer types include bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBCL), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and thymoma (THYM). There are 2908 cancer samples in total (1771 male and 1137 female samples) (Table S1), and the corresponding molecular data and clinical phenotype data were downloaded. A comprehensive analysis was performed to investigate sex-based differences of TMB, TME cells, immune scores, immune-associated genes, and functional pathways, etc., in pan-cancer and each individual cancer type (Fig. 1).

3.1. Sex-biased TMB and immune features

We first tested the difference in pan-cancer TMB between male and female patient groups. TMB of male patients was significantly higher than that of female patients (WRS test $P = 1.2e-07$). As tumor characteristics in the patients in different cancer types are frequently different, we then tested whether there were sex differences within individual cancer types. Seven of these cancers showed significant sex differences (Fig. S2); BLCA, KIRP, LIHC, LUAD, and SKCM were male-biased (WRS test $P = 0.008, 0.00026, 0.041, 0.0078$, and 0.025 respectively); GBM and STAD were female-biased (WRS test $P = 0.028$ and 0.043). The prevalence of TMB of male and female patients across pan-cancer and these seven cancers is shown in Fig. 2A.

To validate the sex-biased TMB, we collected somatic mutation data from the cBioPortal and ICGC data platform (the data sources were listed in Table S3) for the cancers which showed significant sex-biased TMB in TCGA. We obtained almost consistent results in the validation sets, that is, male patients showed higher TMB than female patients in BLCA, LUAD, LINC, SKCM, and renal cell carcinoma (URCC), and the female patients showed higher TMB than male patients in GBM (Fig. S3).

We further tested the sex difference of immune scores, stromal scores, and tumor purity in pan-cancer. We found that the immune scores and stromal scores were female-biased (WRS test $P = 4.5e-06$ and 0.0089) and tumor purity was male-biased (WRS test $P = 5.3e-05$) (Fig. 2B–D). We also analyzed whether there were sex differences of these features within individual cancer types and focused our analysis on each cancer type (Fig. S4–S6). Specifically, the immune scores of female patients in HNSC, LUAD, and LUSC (WRS test $P = 0.018, 0.018$, and 0.0019, respectively) are significantly higher than those in male patients, but lower than those in male patients in KIRP and SARC (WRS test $P = 0.041$ and 0.044) (Fig. S4). For the stromal scores, the female patients showed higher LUAD compared with the male patients (WRS test $P = 0.048$) (Fig. S5), which is lower than the male patients in SARC (WRS test $P = 0.022$). Additionally, the tumor purity in SARC was significantly higher in female patients than male patients (WRS test $P = 0.024$), but lower than male patients in HNSC, LUAD, and LUSC (WRS test $P = 0.038, 0.018$, and 0.034, respectively). The female patients in KIRP also exhibited higher tumor purity than male patients, with statistical significance just exceeding the threshold (WRS test $P = 0.061$) (Fig. S6). Taken together, the male patients generally have higher TMB and tumor purity, but lower immune scores and stromal scores compared with female patients in pan-cancer. However, there are some contrary results in some individual cancer types. For example, the female patients were shown to have higher immune scores and stromal scores, but lower tumor purity compared with male patients in LUAD. In contrast, the female patients had lower immune scores and stromal scores, but higher tumor purity compared with male patients in SARC. Our results...
suggest a divergent sex difference of immune features across different cancer types.

Finally, we tested the sex-biased immune cells across different cancer types. We collected 24 immune cell type-specific gene signatures from the Bindea et al. publication [28] (Table S2). The ssGSEA algorithm was applied to the normalized gene expression data to estimate the relative infiltration level for each cell. To identify sex-biased immune cell infiltration patterns, we compared the cell infiltration levels between female and male patients in each cancer type using the t-test.

The detailed results of sex-biased immune cells for each cancer type are listed in Table S4. With FDR < 0.25, 10 of 19 cancers have at least one sex-biased immune cell. In general, we observed several cancer types to have female-biased immune cells, including HNAC, KIRP, LUAD, and LUSC. For example, 14 of 24 immune cells were shown to have higher relative infiltration levels in the female patients of LUAD (Fig. 3). The two most significant female-biased cells in the cancer are follicular helper T (Tfh) cells and dendritic cells (DC; t-test FDR = 2.24e-06 and 5.72e-
05); the Tfh cells were demonstrated to be involved in the antitumor immunity and were associated with better clinical outcomes in non-small cell lung cancer (NSCLC) [32] and the DC were proposed to be the key factors providing protective immunity against lung cancers [33]. These results suggest that the Tfh cell and
DC activities for male patients in LUAD should be enhanced. In contrast, several cancer types (GBM, KIRC, and SARC, etc.) had male-biased immune cells (Fig. 3). For example, seven immune cells, including plasmacytoid dendritic cells (pDC), neutrophils, eosinophils, T central memory (Tcm) cells, T helper 17 (Th17) cells, cytotoxic cells, and CD8 T cells, were shown to have higher infiltration levels in male SARC patients. Moreover, pDC, which have been shown to contribute to cancer pathogenesis [34] were also observed to be male-biased in HNSC, KRIC, STAD, and THCA. These results suggest that in male patients of these cancers, pDC should be inactivated.

### 3.2. Sex-biased correlation of TMB with immune features

As TMB was proposed to potentially correlated with cancer immune infiltrates in previous studies, we tested the differential correlation of TMB with TME features (immune score, stromal score, tumor purity, and immune cell infiltration level) between male and female...
cancer patients (Table S5). We found that the TMB was negatively correlated with immune score and stromal score, and positively correlated with tumor purity in both male and female pan-cancer patients. Interestingly, these correlations all showed significant sex differences (Fisher’s transformation method, \( P = 0.038, 0.005, \) and \( 0.004, \) respectively), male patients possessing greater correlation than female patients (Fig. 4A).

We then found nine immune cells to have a sex differential correlation with TMB in pan-cancer patients (\( P < 0.05, \) Table S5), including T effector memory (Tem) cell, NK cell, eosinophils, NK CD56dim cell, neutrophils, T helper 1 (Th1) cell, mast cell, T helper (Th) cell and NK CD56bright cell (these cells names are marked with red in Fig. 4A).

The most significant is mast cell (Fisher’s transformation method, \( P = 9.1e-05, \)) which showed a significant negative correlation with TMB in male patients (marked with a red star) but did not show a correlation in female patients. Mast cells are proposed to play important roles in the control of innate and adaptive immunity, endowing them with the ability to tune the nature of host responses to cancer and ultimately influence the outcome and fate of the cancer patient [35].

The second significant cell is the Th cell (Fisher’s transformation method, \( P = 3.9e-04, \)) which showed a greater positive correlation with TMB in male than in female patients. Knutson et al. reported that Th cells were central to the development of an immune response by activating antigen-specific effector cells [36]. These results suggest that it should consider sex differential correlation of some immune features with TMB in the development of immunotherapeutic drugs and methods.

We then tested the sex differential correlation of TMB with immune cell infiltration level across different cancer types (Table S6). For the Th cells, three cancers, DLBC, HNSC, and STAD (Fisher’s transformation method, \( P = 0.026, 0.012, \) and \( 7.7e-04, \)) were found to have a sex-biased correlation with TMB (the cancer names are marked in red in Fig. 4B). Specifically, Th cells showed a significant negative correlation with TMB in female patients of DLBC (Spearman correlation coefficients \( r = -0.64, P = 0.0024 \)) but did not show a significant correlation in male patients of DLBC. Moreover, Th cells were found to have a positive correlation with TMB in female patients of STAD (Spearman correlation coefficients \( r = 0.40, P = 1.9e-04 \)); however, the cells did not found to be significantly correlated with TMB in the male patients of STAD. We also observed that Th cells had a significant negative correlation with TMB only in male patients of HNSC (Spearman correlation coefficients \( r = -0.19, P = 9.2e-04 \)). For mast cells, a sex-biased correlation was found with TMB in KIRP and SKCM (Fisher’s transformation method, \( P = 0.03 \) and \( 0.04, \)) (Fig. 4B).

The mast cells of female patients of KIRP were shown to be negatively correlated with TMB (Spearman correlation coefficients \( r = -0.36, P = 0.053 \)), but the cells of male patients of KIRP did not show a significant correlation with TMB (Spearman correlation coefficients \( r = 0.04, P = 0.69 \)). In SKCM, the mast cells of male patients showed a significantly greater negative correlation with TMB (Spearman correlation coefficients \( r = -0.81, P = 0.0082 \)) compared with female patients. Our results provide insights into the sex differential correlation between TMB and tumor immune cells in different types of cancers.

### 3.3. Sex-biased immune checkpoint genes and immune function pathways

To test whether the immune checkpoint genes (ICG) differ between male and female cancer patients, we collected 68 ICG from the Hu et al. study [37]. The unpaired two-sided \( t \)-test was used to compare the gene expression values between the female and male patients for each cancer type. The statistically significant \( P \)-values were adjusted using the false discovery rate (FDR) method. It was shown that 88% of genes (60/68) were sex-biased, including some well-known ICG such as PDCD1, CD274, and CTLA4. Moreover, we found that seven of 19 cancers have at least one ICG with a sex difference with FDR \( < 0.25: \) BLCA, GBM, HNSC, KIRP, LUAD, LUSC, and PAAD (Fig. 5A). The detailed information on ICG for each cancer type is listed in Table S7. LUAD, LUSC, and HNSC tend to have more female-biased ICG (Female > Male), whereas KIRP and GBM tend to have more male-biased ICG (Male > Female). Specifically, there are 31 female-biased ICG in LUAD; these genes include some genes of the human leukocyte antigen (HLA) family (e.g. HLA-A, HLA-B, HLA-C, HLA-DMA, and HLA-DPB1), CD274, CD40, CD80, CD86, some genes of TNF receptor superfamily (e.g. TNFRSF4, TNFRSF9, TNFRSF18). In contrast, some genes of the HLA family (e.g. HLA-A, HLA-B, HLA-C, HLA-DMA, and HLA-DPB1, etc.) were shown to be male-biased in KIRP. Moreover, several ICG (e.g. CD274, CD276, and TNFRSF4) were found to be female-biased in KIRP (Fig. 5A). It has been reported that the absence of HLA-I (e.g. HLA-A, HLA-B, HLA-C) expression is a common finding in different tumor tissues and is a major mechanism used by tumor cells to escape T cell-mediated immune surveillance [38]. Studies have also shown that the
Sex-specific signatures in the TME

J. Han et al.
expression of PD-L1 protein (encoded by the CD274 gene) in tumor cells has been proposed as a predictive biomarker of response to anti-PD-L1/PD-L1 treatment [39–41]. Our results suggest that sex differences of ICG in the specific cancer types (e.g. KIRP, LUAD, and LUSC) should be considered for the immune checkpoint blockade therapies.

We then test the sex-biased immune function pathways across different cancer types. For each cancer, we compared the gene expression values between female and male patients with the t-test, and a gene ranked list was constructed according to the t-scores of genes. The immune function pathways downloaded from the ImmPort database were mapped on the ranked gene list, and the GSEA method was applied to identify sex-biased pathways. With FDR < 0.25, 16 of 19 cancers have at least one sex difference pathway (Fig. 5B). The detailed information on pathways for each cancer type are listed in Table S8. Interestingly, GBM, KIRP, LGG, LIHC, and SARC tended to have more male-biased pathways, and HNSC, LUAD, LUSC, PAAD, and THYM more female-biased pathways. For the significant immune pathways, the TNF Family Members, receptors, cytokines, cytokine receptors, and chemokines showed a consistently high expression for male patients in GBM, LIHC, and SARC, and for female patients in LUAD, LUSC, and PAAD.

Overall, according to the sex differences of immune-related features, the cancer types could be classified into a ‘strong sex-biased’ immune group and a ‘weak sex-biased’ immune group. For the statistically significant level (P-value) of TMB, immune scores, stromal scores, tumor purity, and immune cells as well as the fraction of significant features for immune cells, immune checkpoint genes, and functional pathways, the cancer types with more than half (at least four of seven features) of significant sex-biased features were labeled as the ‘strong sex-biased’ immune group, and the others as the ‘weak sex-biased’ immune group (Fig. 6). The strong sex-biased immune group includes LUAD, LUSC, HNSC, KIRP, SARC, and GBM, which shows much more extensive sex-biased TME signatures; we should pay attention to the significant sex-biased feature for these cancer types in the immunotherapy of cancer.

3.4. Sex-specific immune cell prognostic markers

The immune cells have been proposed to be associated with the prognosis of cancer patients in our previous study, and we wanted to see whether there were any differences between male and female cancer patient cohorts. For each cancer type, a univariate Cox proportional hazards model was used to estimate the hazard ratio (HR) of overall survival and statistical significance level (P-value) for each immune cell in males and females, respectively (Table S9). Cross cancer assessment of prognostic analysis in male and female patients revealed significant immune cells (Wald P < 0.05) (Fig. S7). Seven recurrently prognostic immune cells (at least four cancer types) were identified in male patient cohorts, including Th2 cell, T cell, DC, and NK cells. Th2 cell was proposed to promote tumor progression through the secretion of cytokines interleukin (IL)-4, IL-6, IL-10, and IL-13 to activate tumor-associated M2 macrophages [42], and which was found to be a risk factor of male patients in SARC, LUAD, KIRP, PAAD, KIRC, and LIHC (HR > 1, Wald P < 0.05). We also found that the T cell played a large role in our fight against cancer as a protective factor in male patients in BLCA, HNSC, LUAD, and PAAD (HR < 1, Wald P < 0.05). Additionally, four recurrently prognostic immune cells (at
Sex-specific signatures in the TME

J. Han et al.

Figure A: Heatmap of gene expression for various genes and diseases.

Figure B: Heatmap of pathway expression for different pathways and diseases.
**Fig. 5.** Sex-biased immune checkpoint genes and immune function pathways across 19 cancer types: BLCA (119 male and 51 female patients), COAD (91 male and 71 female patients), DLBC (16 male and 20 female patients), GMB (36 male and 11 female patients), HNSC (297 male and 111 female patients), KIRC (154 male and 76 female patients), KIRP (83 male and 29 female patients), LAML (27 male and 28 female patients), LGG (55 male and 40 female patients), LiHC (29 male and 18 female patients), LUAD (190 male and 228 female patients), LUSC (309 male and 110 female patients), PAAD (46 male and 40 female patients), READ (21 male and 17 female patients), SARC (68 male and 71 female patients), SKCM (10 male and 12 female patients), STAD (144 male and 83 female patients), THCA (29 male and 77 female patients), THYM (47 male and 44 female patients). (A) Heatmaps of immune checkpoint genes for each cancer type. Differential expression extents (t-scores) of genes between male and female patients are calculated by t-test, and female-biased and male-biased genes are shown in red and blue, respectively. Boxes highlight the statistically significant immune checkpoint genes (FDR < 0.25). (B) Heatmaps of immune function pathways for each cancer type. Sex-biased immune function pathways are identified by GSEA based on the sex-biased gene ranks of mRNA expression for each cancer type, and normalized enrichment score (ES) for each pathway is also calculated by GSEA. Female-biased and male-biased pathways are shown in red and blue, respectively. Boxes highlight the statistically significant enriched pathways (FDR < 0.25).

**Fig. 6.** Classification of cancer types. The cancer types are classified into ‘strong sex-biased’ and ‘weak sex-biased’ immune groups. The statistically significant level (P-value < 0.05) for TMB, immune scores, stromal scores, and tumor purity as well as the fraction of significant features (FDR < 0.25) for immune cells, immune checkpoint genes, and functional pathways were shown for each of cancer types. The ‘strong sex-biased’ immune group and ‘weak sex-biased’ immune group are marked in orange and blue, respectively. The statistical significance (P-value) for TMB, immune scores, stromal scores, or tumor purity was determined by the Wilcoxon rank-sum test.
least four cancer types) were identified in female patient cohorts: Th17 cells, Tem cell, NK cells, and CD8 T cells (Fig. S7). For example, Th17 cell was found to be a protective factor in female patients in LUAD, COAD, STAD, and LAML. Tem cell was found to be a protective factor in female patients in LUAD and PAAD, but a risk factor in female patients in STAD and LUSC. The recurrently prognostic immune cells were observed in male or female patients across different cancer types, highlighting the repurposing potential of immunotherapy drugs targeting these cells.

As LUAD shows much more extensive sex-biased immune-related features (TMB, immune scores, stromal scores, tumor purity, immune cells, immune cells, immune checkpoint genes, and functional pathways) compared with other cancer types (Fig. 6), we took LUAD as an example to investigate further whether the sex-specific signatures based on sex-specific cells could classify the male and female patients into high-risk and low-risk groups, respectively. With Wald $P < 0.05$ in univariate Cox proportional hazards model, we identified eight significant immune cells for female patients (Fig. 7A): Tem cell, Tcm cell, interstitial dendritic cell (iDC), Th17 cell, Thh cell, mast cell, and macrophages are protective factors ($HR < 1$) and Th2 cell, a risk factor ($HR > 1$). In contrast, there were eight significant immune cells for male patients: Tem cell, iDC, pDC, Thh cell, NK cell, T cell, and B cell are protective factors, and Th2 cell, a risk factor. Although four significant cells overlap between male and female patients, their association with the extent of survival differs between these patients. With the sex-specific cells, the male- and female-specific prognostic signatures were constructed. For these signatures, we respectively calculated the risk score of signature for every male and female patient based on the cell infiltration level; the risk score formulas are listed in the Supporting Information and Fig. S8. We then used the Kaplan–Meier method and log-rank test to evaluate the power of classification of risk scores in male and female patients. According to the median of male- and female-risk scores, male and female patients were classified into high-risk and low-risk groups (log-rank test $P < 1.0e-4$ for female patients; $P = 1.8e-4$ for male patients) (Fig. 7B,C). We further performed multivariate Cox proportional hazard regression analysis in male and female LUAD patient groups to test whether the male- and female-risk scores are independent prognostic factors compared with other clinical characters, including age and clinical stage. The results showed that both male- and female-risk scores could serve as independent prognostic factors for OS after multivariable adjustment by clinical characters in male and female LUAD patient groups, respectively (Table S10).

To determine whether the male- and female-specific cells had the same or similar prognostic value in independent datasets, we then applied the same method to classify male and female patients from two independent lung adenocarcinoma datasets, Raponi et al. [43] and GSE68465 [44]. For each independent validation set, male and female patients were respectively divided into high-risk and low-risk groups (log-rank test, $P = 0.055$ and $P = 0.0036$ for male and male patients in Raponi et al. dataset, Fig. 7D and E; $P = 0.0089$ and $P < 1.0e-4$ for female and male patients in GSE68465, Fig. 7F and G). Patients with high-risk scores had significantly shorter overall survival than those with low-risk scores.

Furthermore, several other cancer types (such as LUSC and HNSC) also showed sex-biased features, except LUAD (Fig. 6). Therefore, we also constructed the sex-specific risk score models in the strong sex-biased cancer types. The detailed results are listed in the Supporting Information and Fig. S8.

### 3.5. Sex-biased somatic mutations and their driven immune cells

To identify sex-biased somatic mutations, the genes with high frequency mutations were retained in each cancer type (> 5% mutated samples). We focused on LUAD, which showed significant sex differences in various immune features (TMB, immune score, stromal score, and tumor purity, etc.). Pearson’s Chi-square test was used to identify sex-biased somatic mutations (See Materials and methods). At FDR = 0.25 in the Chi-square test, we identified two female-biased and eight
Sex-specific signatures in the TME

(A) Table showing the hazard ratio (HR) and 95% confidence interval (CI) for different cell types in both female and male groups. The table highlights the statistical significance with * indicating a p-value < 0.05.

(B) TCGA Kaplan-Meier survival plot showing the overall survival for female and male in the high-risk and low-risk groups.

(D) Raponi2006 Kaplan-Meier survival plot showing the overall survival for female and male in the high-risk and low-risk groups.

(F) GSE68465 Kaplan-Meier survival plot showing the overall survival for female and male in the high-risk and low-risk groups.

(C) TCGA Kaplan-Meier survival plot showing the overall survival for male in the high-risk and low-risk groups.

(E) Raponi2006 Kaplan-Meier survival plot showing the overall survival for male in the high-risk and low-risk groups.

(G) GSE68465 Kaplan-Meier survival plot showing the overall survival for male in the high-risk and low-risk groups.
Fig. 8. Sex-biased somatic mutations and their driven immune cells in LUAD. (A) Waterfall plot of sex-biased somatic mutation genes in 237 LUAD samples (126 male and 111 female patients). The statistical significance (P-value) was determined by the Chi-square test, which was then adjusted by FDR. Genes with Chi-square test FDR < 0.25 are shown. Samples are displayed as columns with the sex label on the top, and TMB, immune scores, stromal scores, tumor purity, and different types of somatic mutations are shown below. The bar plots next to the waterfall plot show the mutation frequencies of male and female patients. (B) Sankey diagram demonstrates the immune cells associated with sex-biased somatic mutation genes based on 418 LUAD patients (190 male and 228 female patients). (C) Heatmaps of the infiltration levels of immune cells between patients with mutation of EGFR in based on 418 LUAD patients. (D) Heatmaps of the infiltration levels of immune cells between patients with mutation and no mutation of STK11 based on 418 LUAD patients.
male-biased somatic mutation genes in LUAD (Fig. 8A). The detailed results are listed in Table S11. EGFR mutations were identified to be female-biased (male versus female: 7.2% versus 17.3%, Chi-square test FDR = 0.20) in LUAD patients. Interestingly, the mutations were proposed to be associated with tyrosine kinase inhibitor (gefitinib) response and prolonged survival in NSCLC patients [45], which were also proposed to result in a decline of immune infiltration or a lack of infiltrating immune cells in the NSCLC microenvironment [46]. STK11 was identified to be male-biased (male versus female: 14.8% versus 8%, Chi-square test FDR = 0.15), which was consistent with previous studies [47,48]. However, we found this gene to be more frequently mutated in males than in females for the immune-infiltrated LUAD cohort. Moreover, Koyama et al. proposed that STK11/LKB1 deficiency may promote neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment [49].

Further to estimate which immune cell responses may be potentially triggered by sex-biased mutation genes, we performed the multivariate logistic regression analysis on gene mutation status and cell infiltration levels in LUAD (Fig. 8B); eight of 10 sex-biased mutation genes were associated with at least one immune cell. The statistically significant cells associated with these mutations are listed in Table S12. For example, we found that EGFR mutations were associated with six immune cells (multivariate logistic regression P < 0.05), five of which are downregulated (Th2 cells, cytotoxic cells, Tcm cells, Th17 cells, T gamma delta (Tgd) cells), and one cell upregulated (T helper cell) in EGFR mutation patients (Fig. 8C). For the patients with STK11 mutations, three cells were downregulated (aDC, macrophages, and NK cells) and three cells upregulated (Th17 cells, Th2 cells, and Mast cells) (Fig. 8D). These results may help understanding of potential immune cells driven by sex-specific mutations in order to implement precise treatment.

3.6. Sex differences of TMB’s ability in predicting the response to immunotherapy

TMB was proposed to be a predictive biomarker of the immune checkpoint blockade therapy response in previous studies. We wanted to know whether the TMB predictive power showed sex differences. Three public ICB cancer therapy datasets (anti-PD-1, anti-PD-L1, or anti-CTLA-4), including pan-cancer [50], non-small cell lung cancer [51], and clear cell renal cell carcinoma [52], were collected from the cBioPortal website (http://www.cbioportal.org/). TMB was used to predict the response to ICB therapies in male and female patients, respectively, for each dataset. The receiver operating characteristic curve analysis was performed, and the area under the curve (AUC) was used to evaluate the predictive power of TMB. The results showed that the AUC in female patients is larger than in male patients for each dataset (Fig. S9), which indicates that TMB has a better predictive power for females than for males in cancer. These results are consistent with a previous study [53], which tested sex differences in the performance of TMB in ICB response prediction only in lung cancer. The female-favored predictive power of the TMB may be due to the female patients having a stronger immune score (immune microenvironment) compared with male patients (Fig. 2B). The female patients with high TMB are highly immunogenic and may exhibit stronger immunosuppressive signals. ICB therapy may block these signals between tumor cells and immune cells, and thus the tumor can be attacked more effectively in female patients than in male patients.

4. Discussion

Sex is a key factor that has been proposed to be associated with cancer initiation, progression, and prognosis outcome in multiple cancer types [1,2]. Although the significance of the sex effect in cancer immune responses is known from some of the literature [5,8], its immune microenvironment characterization has largely remained elusive. A comprehensive analysis of immune-related feature differences between male and female cancer patients is urgently needed. Our study focuses on sex-based differences of TMB, TME features (immune scores, stromal scores, tumor purity, and immune cells), immune checkpoint-related genes and functional pathways, etc., in immune-infiltrated cancer patients.

We discovered large sex differences of TMB in pancreatic and several individual cancer types. For example, the male patients in BLCA, KIRP, LIHC, LUAD, and SKCM showed higher TMB than female patients, and the female patients in GBM and STAD showed higher TMB than male patients (Fig. 2A). We validated these results in the independent validation data obtained from the cBioPortal and ICGC data portal (Table S3, Fig. S3). The limitation of our analysis is that the validation datasets which include cancer patients with the somatic mutation, expression, and clinical characteristics data are rare, and more cancer datasets must be obtained to validate our results in the future.

As TMB reflects the tumor antigenicity generated by somatic tumors, it may be more suitable to use patients...
with lower TMB for antigenicity-enhancing strategies for tumor cells, such as radiation therapy and DNA-damaging chemotherapy. Moreover, we discovered that female patients in HNSC, LUAD, and LUSC showed higher immune scores than male patients, and male patients in KIRP and SARC showed higher scores than female patients (Fig. S4). The stromal scores were higher in female patients than male patients in LUAD, and lower than male patients in SARC (Fig. S5). The immune and stromal scores reflect the immune microenvironment state, and the patients with lower immune and stromal scores may be more suitable for immune microenvironment-enhancing strategies, such as hormone therapy and cytokine therapy, which may promote an immune response.

In a previous study, Wang et al. proposed that sex differences in immune response may be caused by differences in the expression of sex chromosome-linked genes, in hormone levels, in developmental biology, etc.[6]. According to our analysis, LUAD, LUSC, HNSC, KIRP, SARC, and GBM were identified to be strongly sex-biased in TME (Fig. 6). The potential mechanism of sex difference in TME may be the consequence of sex-biased tumor molecular characteristics, such as somatic mutation, expression of immune checkpoint genes, which may perturb biological pathways and change prognostic biomarker performance.

5. Conclusions

Overall, the cancer immune system is complex, and may differ between male and female patients. Our study performed a comprehensive analysis to investigate sex-based differences of tumor microenvironment-related features across a broad range of cancer types. Our results thus provide a valuable starting point from which the role of sex can be explicitly considered in future ICB trials, identification of immune-related biomarkers, and cancer immunotherapy.

Acknowledgements

This work was supported in part by National Natural Science Foundation of China (grant no. 62072145), Natural Science Foundation of Heilongjiang Province (grant no. LH2019C042), and Postdoctoral Scientific Research Developmental Foundation of Heilongjiang Province (grant no. LBH-Q18077).

Conflict of interests

The authors declare that they have no competing interests.

Author contributions

JH and YZ conceived and designed the study. YY and XL developed the methodology. JL and QW acquired the data. YS, JQ and YH analyzed the data and implemented the methodology. YY, YS and JW provided constructive discussions. JH and LC drafted the manuscript. All the authors read and agreed to the manuscript.

Data accessibility

The data that support the findings of this study are available on request from the corresponding author.

References

1. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818–24.
2. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2011;29:737–46.
3. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011;20:1629–37.
4. Edgren G, Liang L, Adamo HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27:187–96.
5. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.
6. Wang S, Cowley LA, Liu XS. Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules. 2019;24:3214.
7. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–86.
8. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet. 2018;19:737–46.
9. Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:529–36.
10. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–6.
11 Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol.* 2016b; 17:218.
12 De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell.* 2013; 23:277–86.
13 Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Curr Opin Immunol.* 2014; 27:1–7.
14 Becht E, Giraldo NA, Germain C, de Reynies A, Laurent-Puig P, Zucman-Rossi J, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and therapeutic classifications of cancers. *Adv Immunol.* 2016a; 130:95–190.
15 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol.* 2013; 14:1014–22.
16 Senbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol.* 2016; 17:231.
17 Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmunoCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. *Adv Sci.* 2020; 7:1902880.
18 Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods.* 2015; 12:453–7.
19 Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol.* 2017; 18:220.
20 Wang F, Xie X, Song M, Ji L, Liu M, Li P, et al. Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma. *Ann Transl Med.* 2020; 8:750.
21 Xie F, Bai Y, Yang X, Long J, Mao J, Lin J, et al. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. *Int Immunopharmacol.* 2020; 89:107135.
22 Johnson DB, Frampton GM, Ritho MJ, Yusko E, Xu Y, Guo X, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. *Cancer Immunol Res.* 2016; 4:959–67.
23 Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, et al. Comprehensive cancer gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. *Oncotarget.* 2015; 6:34221–7.
24 Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet.* 2016; 387:1909–20.
25 Li CH, Haider S, Shiah YJ, Thai K, Boutros PC. Sex differences in cancer driver genes and biomarkers. *Can Res.* 2018; 78:5527–37.
26 Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med.* 2017; 9:34.
27 Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. *Nat Commun.* 2018; 9:5361.
28 Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity.* 2013; 39:782–95.
29 Yoshihara K, Shahmoradgoli M, Martinez E, Vesgesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nat Commun.* 2013; 4:2612.
30 Fukushima A. DiffCorr: an R package to analyze and visualize differential correlations in biological networks. *Gene.* 2013; 518:209–14.
31 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *JR Stat Soc B.* 1995; 57:289–300.
32 Ma QY, Huang DY, Zhang HJ, Chen J, Miller W, Chen XF. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer. *Int Immunopharmacol.* 2016; 41:1–7.
33 Wang JB, Huang X, Li FR. Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. *Cancer Commun.* 2019a; 39:43.
34 Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and immunotherapy. *J Neuroimmunol.* 2018; 322:63–73.
35 Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, et al. The significant role of mast cells in cancer. *Cancer Metastasis Rev.* 2011; 30:45–60.
36 Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. *Cancer Immunol Immunother.* 2005; 54:721–8.
37 Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. *Brief Bioinform.* 2021; 22:176.
38 Garrido F, Ruiz-Cabello F, Aptsiauri N. Rejection versus escape: the tumor MHC dilemma. *Cancer Immunol Immunother.* 2017; 66:259–71.
Sex-specific signatures in the TME

J. Han et al.

39 Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359–70.

40 Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74.

41 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.

42 DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.

43 Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Can Res. 2006;66:7466–72.

44 Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat Med. 2008;14:822–7.

45 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

46 Xia W, Mao W, Chen R, Lu R, Liu F, He Y, et al. Epidermal growth factor receptor mutations in resectable non-small cell lung cancer patients and their potential role in the immune landscape. Med Sci Monit. 2019;25:8764–76.

47 Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.

48 Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29:71–22.

49 Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76:999–1008.

50 Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018b;50:1271–81.

51 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124–8.

52 Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801–6.

53 Wang S, Zhang J, He Z, Wu K, Liu XS. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex. Int J Cancer. 2019c;145:2840–9.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Flow chart of sample filtering.

Fig. S2. Box plots of TMB between male and female patients.

Fig. S3. Box plots of TMB between male and female patients in the validation sets.

Fig. S4. Box plots of immune scores between male and female patients.

Fig. S5. Box plots of stromal scores between male and female patients.

Fig. S6. Box plots of tumor purity between male and female patients.

Fig. S7. Dot plot of univariate hazard ratios (HR) and P-values (Wald-test) for each of the immune cells significantly associated with overall survival of patients (P-value < 0.05) in male patient groups (119 male BLCA, 91 male COAD, 36 male GMB, 297 male HNSC, 154 male KIRC, 83 male KIRP, 27 male LAML, 29 male LIHC, 190 male LUAD, 309 male LUSC, 46 male PAAD, 68 male SARC, and 47 male THYM patients) and female patient groups (51 female BLCA, 71 female COAD, 11 female GMB, 76 female KIRC, 28 female LAML, 18 female LIHC, 228 female LUAD, 110 female LUSC, 71 female SARC, 83 female STAD, and 40 female PAAD patients).

Fig. S8. Kaplan–Meier survival curves of patients classified into high- and low-risk groups using the male- and female-specific prognostic score models in male and female cohorts.

Fig. S9. ROC curve for ICB therapy response prediction with TMB in male and female patients respectively.

Table S1. Summary of TCGA cancer types and immune infiltrated male and female patient samples used in the study.

Table S2. 24 different immune cell types in Bindea et al. publication and their marker genes.

Table S3. The validation datasets.

Table S4. Differential immune cells between male and female patients across 19 cancer types.
**Table S5.** Differential correlation of TMB with TME features (immune score, stromal score, tumor purity, and immune cell infiltration level) between male and female pan-cancer patients.

**Table S6.** Differential correlation of TMB with immune cell infiltration level across different cancer types.

**Table S7.** Differentially expressed immune checkpoint genes between female and male (female/male) patients across 19 cancer types.

**Table S8.** Differential immune function pathways between female and male (female/male) patients across 19 cancer types.

**Table S9.** Hazard ratio (HR) and P-value of overall survival for each immune cell in male and female patients, respectively, across 19 cancer types.

**Table S10.** Univariable and multivariable Cox regression analyses of male-risk score/female-risk score and clinicopathological factors in LUAD-male/LUAD-female cohort.

**Table S11.** Association of somatic mutation genes with patient sex bias on Chi-square test in LUAD.

**Table S12.** Immune cells associated with sex-biased mutation genes based on the multivariate logistic regression analysis in LUAD.